PROGRAMME Poster Presentations

P01 - Diagnosis of Helicobacter infection

 

P01.01
Comparison of four stool antigen tests for the detection of Helicobacter pylori
Reza Soleimani, Yvoir, Belgium


P01.02
Screening and diagnosis of Helicobacter pylori infection and autoimmune gastritis in patients with chronic pancreatitis
Mila Kovacheva-Slavova, Sofia, Bulgaria


P01.03
The Presence of Anti-Parietal Cell Auto-antibodies Could be Related with the Re-infection of Helicobacter pylori.
Saenal Lim, Paldal-gu, Suwon, Gyeonggi-Do, Korea, Republic of


P01.04
Automation of RIDA®GENE Helicobacter pylori PCR on the Ingenius® automated system.
Philippe Lehours, 33076, France


P01.05
Comparison of different methods for the detection of Helicobacter pylori in the pathology diagnostics
Gábor Lotz, Budapest, Hungary


P01.06
PCR improved detection of Helicobacter pylori in unselected adult patients undergoing routine gastroscopy
Thomas Butler, Dublin, Ireland


P01.07
CagA and VacA genotypes of Helicobacter pyloristrains in Estonia and their resistance to antibiotics
Kaisa Roots, Tallinn, Estonia


P01.08
Real-time PCR Helicobacter pylori test in comparison with culture and histology for Helicobacter pylori detection and identification of resistance to clarithromycin: single center experience
Kateryna Priadko, Nantes, France


P01.09
Evaluation of the accuracy of the "LIAISON® Meridian Helicobacter pylori SA" stool antigen test for the diagnosis of H. pylori infection: a Spanish multicentre study.
Elena Resina-Sierra, Madrid - Madrid, Spain

 

P01.10

Presence of H. pylori and NHPH in children with gastroduodenal manifestations at the National Institute of Pediatrics in México.

Carolina Romo-González, Mexico, Mexico


P02 - Treatment of Helicobacter infection

 

P02.01
Effectiveness and safety of amoxicillin‐ and furazolidone-containing bismuth quadruple regimen for Helicobacter pylori infection in real‐world practice
jianxiang peng, nanchang, China


P02.02
The in vitro activity of poplar propolises against Helicobacter pylori growth and urease activity
Izabela Korona-Glowniak, Lublin, Poland


P02.03
Withdrawn


P02.04
Withdrawn


P02.05
Seven days of Bismuth-based quadruple therapy is effective for the first-line treatment of Clarithromycin-resistant confirmed Helicobacter pylori infection
Hyeyeon LEE, Seoul, Korea, Republic of


P02.06
Withdrawn


P02.07
Role of compliance in Helicobacter pylori treatments: results from the European Registry on H. pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain


P02.08
Annual eradication rates of concomitant therapy as first-line treatment for Helicobacter pylori infection: A 10-year retrospective data from a single center in Korea
Sung Woo Jung, Ansan, Korea, Republic of


P02.09
Recurrent Non-variceal Upper Gastrointestinal Bleeding among Patients Receiving Dual Anti-platelet Therapy
Moon Kyung Joo, Seoul, Korea, Republic of


P02.10
Effectiveness of high-dose rabeprazole triple therapy for H. pylori infection in elderly people and atrophic gastritis
Jeong Seop Moon, Seoul, Korea, Republic of


P02.11
Differences of Helicobacter pylori diagnostics and treatment in the elderly and non-elderly populations: data from European registry on H. pylori management (Hp-EuReg)
Paulius Jonaitis, Kaunas, Lithuania


P02.12
EFFICACY OF CULTURE-BASED TAILORED THERAPY AS PRIMARY TREATMENT OF HELICOBACTER PYLORI INFECTION: UPDATED REPORT OF A MULTICENTER PROSPECTIVE STUDY
Hwoon-Yong Jung, Seoul, Korea, Republic of


P02.13
The eradication rate of Helicobacter pylori of concomitant therapy was higher than sequential therapy and triple therapy with tegoprazan, potassium competitive acid blocker
Yeonjoo Seo, seoul, Korea, Republic of


P02.14
The Influence of Probiotic Supplementation on the Eradication rates and Recrudescence of Helicobacter pylori: A Double-Blind Randomized Clinical Trial
Na Rae Lim, Suwon, Korea, Republic of


P02.15
A randomized multicenter controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA gene point mutations
Samryong Jee, Busan, Korea, Republic of


P02.16
Serbian data overview from April 2021 to April 2022: evaluation from the European registry on H. pylori management (Hp-EuReg)
Vladimir Milivojevic, Belgrade, Serbia


P02.17
The Effect of Vitamin C Supplement to Standard TripleTherapy for Eradication of Helicobacter pylori
Abdurrazag Nami, Algarabolli, Libyan Arab Jamahiriya


P02.18
Empirical first-line treatment use and effectiveness trends in Europe in the period 2013-2021: Results from the European Registry on H. pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain


P02.19
Bismuth quadruple regimen containing furazolidone and tetracycline achieved excellent eradication efficacy against Helicobacter pylori, both for initial treatment and rescue treatment
jianxiang peng, nanchang, China


P02.20
Efficacy and safety of Gastrocur® in combination with pantoprazole in patients with Helicobacter pylori
Dmitry Bordin, Moscow, Russian Federation


P02.21
Effectiveness and safety of high-dose dual therapy: Results of the European Registry on the Management of Helicobacter Pylori Infection (Hp-EuReg)
Olga P. Nyssen, Madrid, Spain


P02.22
Lessons in Helicobacter pylori treatment failure:a restrospective study
Jinliang Xie, Nanchang , Jiangxi Province, China


P02.23
Withdrawn


P02.24
Clinical phenotypes through machine learning of first-line treated patients in Europe during the period 2013-2021: data from the European Registry on H. pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain


P02.25
Reinforced medication adherence improves H.pylori eradicationrate in developing countries: a systematic review and meta-analysisof randomized controlled trials
Rong Zeng, Nanchang, China


P02.26
ANALYSIS OF DYNAMICS OF DIAGNOSIS AND TREATMENT OF HELICOBACTER PYLORI IN UKRAINE
Yana Nikiforova, Kharkiv, Ukraine


P02.27
The comparison of standard triple therapy effectiveness after addition of Saccharomyces boulardii
Olga Sjomina, Riga, Latvia


P02.28
Experience with single-capsule bismuth quadruple therapy in 6,000 patients from the European Registry on H. pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain


P02.29
Tailored therapy with Bismuth add-on standard triple therapy versus Concomitant therapy: As a first-line regimen of Helicobacter pylori infection
Soo Yeon Choi, Suwon-si, Gyeonggi-do, Korea, Republic of


P02.30
Comparison of tegoprazan-based versus lansoprazole-based Helicobacter pylori eradication therapy: A propensity score matching analysis
Dong-Chan Joo, Busan, Korea, Republic of


P02.31
An evolving resistant pandemic. Rising community H. pylori treatment failure to clarithromycin-based triple therapy, an observational study
Thomas Butler, Dublin, Ireland


P02.32
Effectiveness of treatments against Helicobacter pylori according to resistance to clarithromycin: data from the European Registry on Helicobacter pylori Management (Hp-EuReg)
Olga Nyssen, Madrid, Spain


P02.33
Using Watercress Extract against the virulence factor Urease as a potential treatment for Helicobacter pylori Infection
Kyle Stewart, Bath, United Kingdom


P02.34
Why vonoprazan dual and triple therapies failed to achieve acceptable cure rates in the US/European trial Why vonoprazan dual and triple therapies failed to achieve acceptable cure rates in the US/European trial
David Graham, Houston, United States


P02.35
14-day Vonoprazan-based quadruple therapy for Helicobacter pylori eradication in areas with high clarithromycin resistance: A prospective randomized study (VQ-HP trial)
Nuttapat Tungtrongchitr, Pathumthani, Thailand


P03 - Gastric cancer

P03.01
Local recurrence after endoscopic submucosal dissection of early gastric cancer
Cheol Woong Choi, Yangsan, Korea, Republic of


P03.02
Long term outcomes of endoscopic treatment for early gastric cancer in extremely elderly patients
Jae J Kim, Seoul, Korea, Republic of


P03.03
Hydrogen sulfide donor diminishes Helicobacter pylori infection-induced procarcinogenic human gastric fibroblasts activation
Tomasz Brzozowski, Cracow, Poland


P03.04
Association of Helicobacter pylori infection and oral hygiene in patients with gastric adenocarcinoma in São Paulo, Brazil
Tatiane Tiengo, São Paulo, Brazil


P03.05
The effect of Helicobacter pylori treatment on the risk of gastric cancer in general population. A nationwide population-based cohort study
Woon Geon Shin, Seoul, Korea, Republic of


P03.06
Humoral immunity in patients with chronic gastritis, chronic atrophic gastritis and gastric cancer with H.pylori infection.
Aleksandr Sinyakov, Krasnoyarsk, Russian Federation


P03.07
Chemiluminescent activity of neutrophilic granulocytes in patients with gastric diseases associated with H. pylori infection.
Aleksandr Sinyakov, Krasnoyarsk, Russian Federation


P03.08
Risk of gastric cancer among patients with newly diagnosed ulcerative colitis: A nationwide population based study.
Hyun Soo Kim, Wonju, Korea, Republic of


P03.09
Outcomes of conventional method versus pocket-creation method for endoscopic submucosal dissection of gastric body tumors using a dual knife
Sang Pyo Lee, Hwaseong, Korea, Republic of


P03.10
A modified endoscopic full thickness resection for gastric subepithelial tumors from muscularis propria layer
seok choi, busan, Korea, Republic of


P03.11
Long-term Clinical Outcomes of Endoscopic Treatment of Gastrointestinal Stromal Tumors in Stomach
Moon Kyung Joo, Seoul, Korea, Republic of


P03.12
Serum levels of interleukin-16 in patients with Helicobacter Pylori infection
Shatha Alzahrani, nottingham, United Kingdom


P03.13
Clinical Outcomes of Endoscopic Submucosal Dissection for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Case Series
Kee Don Choi, Seoul, Korea, Republic of


P03.14
Reflux esophagitis associated with false negative cases in pepsinogen testing for precancerous gastric lesions
Danute Razuka-Ebela, Riga, Latvia


P03.15
Current Status of Therapeutic Endoscopy and Changes in Gastric Cancer Incidence in Korea
Su Heon Park, Seoul, Korea, Republic of


P03.16
The volatilomic signature of Helicobacter pylori
Daria Slefarska-Wolak, Kielce, Poland

P04 - Helicobacter infection - pathogenesis and host response

 

P04.01
Modulation of the Helicobacter pylori interaction with host cells through Mycobacterum bovis Onco-BCG bacilli in vitro and in vivo
Weronika Gonciarz, Lódz, Poland


P04.02
Gastric coinfection with thiopeptide-positive Cutibacterium acnes alters Helicobacter pylori-induced pathogenesis in murine model of gastric cancer
Courtney Lunger, Cambridge, United States


P04.03
Helicobacter pylori and SARS-CoV-2 association: a coincidence or a pathogenetic correlation?
Giovanni Gasbarrini, Rome, Italy


P04.04
Enterohepatic Helicobacter species differentially modulate the gastrointestinal microbiome & It can impact Helicobacter pylori pathogenesis
Zhongming Ge, Cambridge, United States


P04.05
Typhlocolitis associated with H. mastomyrinus in gpt delta C57BL/6J transgenic colony with a naturally acquired immunodeficiency
Amanda Armijo, Cambridge, United States


P04.06
Helicobacter pylori infection induces ferroptosis in gastric epithelial cells and mediates inflammatory responses
Huan Wang, Nanchang, China


P04.07
Regression of follicular gastritis after successful eradication of Helicobacter pylori
Yoo Min Han, Seoul, Korea, Republic of


P04.08
The Notch pathway transcription factor HES1 regulates expression of the pro-inflammatory cytokine IL-8 during H. pylori infection
Rebecca FitzGerald, Dublin, Ireland


P04.09
Interference of LPS H. pylori with IL-33-Driven Regeneration of Caviae porcellus Primary Gastric Epithelial Cells and Fibroblasts
Weronika Gonciarz, Lódz, Poland


P04.10
The interplay between Helicobacter pylori virulence gene expression and host cell responses
Tanvi Somiah, Stockholm, Sweden


P04.11
Withdrawn


P04.12
Withdrawn


P04.13
Matrix metalloproteinase (MMP)-7 mRNA abundance is increased in gastric mucosa of patients with H. pylorigastritis and gastric pre-neoplasia
Mushfique Alam, Liverpool, United Kingdom


P04.14
A miRNA-mRNA network to study their role in Helicobacter pylori induced gastric cancer
Oindrilla Mukherjee, Durgapur, India


P04.15
Study of Neutrophil Extracellular Traps (NETs) in Helicobacter pylori infection
Beatriz Martinez-Gonzalez, ATHENS, Greece


P04.16
Helicobacter pylori infection inhibits p53 and promotes mitophagy through MITF
Jianfang Rong, Nanchang, China


P04.17
The role of paraoxonase 1 in helicobacter induced gastritis
Sung Soo Kim, Uijongbu, Korea, Republic of


P04.18
Helicobacter pylori infection inhibits p53 and promotes glycolysis through PGK1
Jianfang Rong, Nanchang, China


P04.19
Salvia cadmica extracts rich in polyphenols neutralize a deleterious effects of oxidative stress driven by Helicobacter pylori lipopolysaccharide in cell cultures of gastric epithelial cells or fibroblasts
Weronika Gonciarz, Lódz, Poland

P04.20

Trefoil Factor 1 silencing during Helicobacter pylori chronic infection

Alessandra Tosco, Salerno, Italy

P05 – Epidemiology

 

 

P05.01

Helicobacter pylori resistance to antibiotics in HIV- coinfected individuals in the recent years
Marcel Nkuize, Brussels, Belgium


P05.02
Withdrawn


P05.03
Seroprevalence of Anti CagA Helicobacter pylori Among Libyan Dyspeptic Children From Urban and Rural Community
Abdurrazag Nami, Algarabolli, Libyan Arab Jamahiriya


P05.04
The Current Prevalence of Helicobacter pylori Infection Among Libyan Type Two Diabetic Mellitus Patients: A multicenter Study
Abdurrazag Nami, Tripoli, Libyan Arab Jamahiriya


P05.05
Identification of drinking water sources in patients with Helicobacter pylori infection from Bacau county, Romania
Elena Popovici, Bacau, Romania


P05.06
Exploratory analysis of the eating habits of patients with gastric adenocarcinoma: a case-control study in the Central Brazil Region.
Tatiane Tiengo, São Paulo, Brazil


P05.07
Evaluation of intra-family agglomeration in the transmission of Helicobacter pylori infection in patients from Bacau county, Romania
Elena Popovici, Bacau, Romania


P05.08
Association of alcohol consumption and Helicobacter pylori infection in central Brazil
Tatiane Tiengo, São Paulo, Brazil


P05.09
Association of tobacco consumption and Helicobacter pylori infection in dyspeptic patients in central Brazil
Tatiane Tiengo, São Paulo, Brazil


P05.10
Research trends on the relationship between microbiota and Helicobacter pylori from 1983 to 2021: a bibliometric analysis
Huan Wang, Nanchang, China


P05.11
The frequency of erosions and ulcers of the stomach and duodenum in patients with COVID-19 infection
Vladislav Tsukanov, Krasnoyarsk, Russian Federation


P05.12
NATIONWIDE STUDY OF PREVALENCE RATES AND ANTIBIOTIC RESISTANT PATTERNS OF H. PYLORI INFECTION IN THAILAND COMPARING TO ASEAN COUNTRIES
Sarita Ratana-Amorpin, Bangkok, Thailand


P05.13
Potential risk of proton pump inhibitors for Parkinson's disease: a nationwide nested case-control study
hye-kyung jung, seoul, Korea, Republic of


P06 - Microbiology and genomics of Helicobacter

 

 

P06.01
Withdrawn


P06.02
Novel Helicobacter spp. isolated from wild mice in Massachusetts, United States
Zeli Shen, Cambridge, United States


P06.03
LncRNA LUCAT1 increases the oncogenic properties of gastric cancer cells and macrophages by regulating MIF expression in H. pylori-induced gastric cancer.
Seoyeon Kim, Seoul, Korea, Republic of


P06.04
Association of the Helicobacter pylori virulence gene oipA with the severity of gastroduodenal diseases
Tatiane Tiengo, São Paulo, Brazil


P06.05
Refractory H.pylori infection and Gastric Microbiota
jinyun wang, Nanchang, China


P06.06
Whole genome sequencing of vacA allelic variants of the mouse colonising Helicobacter pylori strain PMSS1
Joanna Stephens, Nottingham, United Kingdom


P07 - Helicobacter and extragastroduodenal disease

 

 

P07.01
Association between Helicobacter pylori and hypertension in dyspeptic patients in central-western Brazil
Tatiane Tiengo, São Paulo, Brazil


P07.02
Association between Helicobacter pylori infection and anemia in dyspeptic patients seen at a reference hospital in central-western Brazil
Tatiane Tiengo, São Paulo, Brazil


P07.03
Effects of Helicobacter pylori on faecal calprotectin in development colorectal carcinoma
Marko Nikolic, Zagreb, Croatia


P07.04
Helicobacter pylori induces hepatic lesions in a mouse model of gastric carcinogenesis
Christine Varon, Bordeaux, France


P08 - Microbiota in health and disease

 

P08.01
Urease as motor protein for translocation of extracellular vesicles of gastric yeast
Atousa Hatefi, Tehran, Iran, Islamic Republic of


P08.02
Extracellular vesicles from H. pylori & gastric yeast exhibit urease activity
Atousa Hatefi, Tehran, Iran, Islamic Republic of


P08.03
Identification of non-H. pylori gastric bacteria which stimulate interleukin-8 production in gastric epithelial cells
Jae Gyu Kim, Seoul, Korea, Republic of


P08.04
Treatment of non-erosive reflux disease and change of esophageal microbiome: A prospective multicenter study
Sang Kil Lee, Seoul, Korea, Republic of


P08.05
Neurotoxic and pro-inflammatory properties of Proteus mirabilis urease
Celia Carlini, Porto Alegre, Brazil


P08.06
Proton pump inhibitors use and the risk of rheumatoid arthritis; A Nationwide Cohort Study
Tae Jun Kim, Seoul, Korea, Republic of


P08.07
Withdrawn


P08.08
Withdrawn


P08.09
DSS-induced intestinal hyperpermeability is microbiome-dependent and displays regional variability
Nikita Hanning, Wilrijk, Belgium


P08.10
GLUTEN FREE DIET BASED ON PASTA MADE WITH SORGHUM FLOUR REDUCES GASTROINTESTINAL SYMPTOMS AND AMELIORATES DYSBIOSIS
Giovanni Gasbarrini, roma, Italy


P08.11
Fecal microbiome transplantation for recurrent CDI: treatment efficacy and safety with oral capsules
Tadas Urbonas, Kaunas, Lithuania


P08.12
The use of fecal microbiota transplantation for recurrent Clostridioides difficileinfection: Brazilian experience
Luis Coellho, Belo Horizonte, Brazil


P08.13
Sterile fecal filtrate transfer for the treatment of hepatic encephalopathy
Rolandas Gedgaudas, Kaunas, Lithuania


P08.14
Optimization of samples preparation conditions for circulating microbiome studies
Darja Nikitina, Kaunas, Lithuania


P08.15
A novel Campylobactersp. and Helicobacter hepaticus isolated from Nile rats (Arvicanthis niloticus)
Zeli Shen, Cambridge, United States